Shares of Myriad Genetics MYGN remained flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share rose 25.00% over the past year to ($0.06), which beat the estimate of ($0.14).
Revenue of $173,100,000 rose by 5.55% year over year, which beat the estimate of $156,200,000.
Recent Stock Performance
52-week high: $33.97
52-week low: $10.54
Price action over last quarter: Up 1.00%
Company Overview
Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual's risk of developing a disease. The firm produces myRisk, a 35-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.